Phase
Condition
Colorectal Cancer
Cancer/tumors
Carcinoma
Treatment
N/AClinical Study ID
Ages 18-70 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
aged 18-70 years with histologically or cytologically confirmed advanced colorectaladenocarcinoma
Eastern Cooperative Oncology Group performance status of 0 to 2
life expectancy of ≥ 3 months
patients who had failed first-line treatment with either XELOX (capecitabine combinedwith oxaliplatin) or FOLFOX (5-fluorouracil/leucovorin with oxaliplatin)
at least one measurable disease lesion according to the Response Evaluation Criteriain Solid Tumors (RECIST 1.1) criteria
have adequate bone marrow, hepatic, and renal function
Exclusion
Exclusion Criteria:
patients with previous chronic inflammatory bowel disease, chronic diarrhea orrecurrent bowel obstruction
patients with symptomatic brain metastases
active clinical severe infection
previously received irinotecan
dihydropyrimidine dehydrogenase (DPD) enzyme adequate